Release issued 21st May 2007

The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a British company and is the UK’s top award for business performance.

Over the past three years Bridgehead’s export sales have more than trebled, as the company has strengthened its position as a leading supplier of pricing, reimbursement and market access support to the global pharmaceutical industry.

Timothy Fitzgerald, Bridgehead CEO, said: “We are obviously delighted that our business performance merits such a prestigious award. Two years ago, less than half of our business was from international clients, while today it has grown to nearly 80%. This success is down to the hard work and professionalism of both our UK-based team and our network of over 50 associates across the major European, North American and Asian markets.”

Bridgehead provides a range of specialist consultancy services to the pharmaceutical and biotechnology sectors, including technical and commercial due diligence and pricing, reimbursement and market access strategy.

In the market access field, Bridgehead is able to draw on a wide range of skills and experience, including direct experience from both an industry and a payer perspective, to advise companies in all stages of product development and commercialisation.

Services range from initial market assessments, focusing on pricing and reimbursement potential and risks, through the development of value messages to meet the concerns of payers and budget holders, to the formulation of pricing and reimbursement strategies and supporting clients through their implementation.

Bridgehead is widely recognised as the leading provider of independent Experts’ Reports to support stock exchange fundraising on both the UK’s main market and AIM. Companies that have been reviewed by Bridgehead as part of stock market listings and other investment rounds include Lombard Medical plc, Vectura Group plc, Inion Ltd, ProStrakan Group plc, Alizyme plc, Cardiomag Imaging Inc, GeneMedix plc, GW Pharmaceuticals plc, Akers Bioscience Inc, CustomVis plc and Napo Pharmaceuticals inc.

In 2006, Bridgehead carried out independent due diligence on behalf of AGI as part of a €42.5 million AIM placing. Commenting on the work by Bridgehead, Dr John Devane, Chief Executive Officer of AGI Therapeutics, said: “We asked Bridgehead to work to a very aggressive timescale and we were very impressed that they met our needs while producing a very comprehensive and professional report. The Bridgehead staff were well informed, very thorough in their assessment and rigorous in their analysis and findings. The timely delivery of their expert’s report was critical to our successful admission to AIM/IEX and I have no hesitation in recommending them.”

(15th January 2007) New report from Pharmalicensing highlights the R&D opportunities in China

(6th June 2006) Pharmalicensing re-launches reports on the top 50 biopharmaceutical companies

(15th May 2006) Bridgehead International publishes guide to pharma & biotech opportunities in India

(27th April 2006) Pharmalicensing reports on five year therapy area-specific deals and alliances

(27th February 2006) Bridgehead International provides Experts' Report for listing of AGI Therapeutics plc on AIM and IEX